{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T23:53:56Z","timestamp":1773100436686,"version":"3.50.1"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T00:00:00Z","timestamp":1636070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p><jats:bold>Introduction:<\/jats:bold> Few studies have examined the association between the rate of treatment response and the outcome of pediatric Guillain-Barr\u00e9 syndrome (GBS). Therefore, our study aimed to identify treatment response in relation to the short-term outcomes of GBS. Further, we investigated its potential predictive value for prognosis.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Our retrospective study included children diagnosed with GBS in the Pediatric Neurology Department of the Children's Hospital of Hebei Province from 2016 to 2020. According to the rate of response from the standard intravenous immunoglobulin (IVIg) treatment, patients were divided into two groups: rapid-response GBS (initial response within 7 days) and slow-response (initial response within 8\u201330 days). The GBS disability score (Hughes Functional Grading Scale) was used to assess the children's functional disability at nadir, 1 month, and 6 months after onset.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Among the 36 children included in the study, 18 (50%) and 18 (50%) were rapid and slow responders, respectively. Time from IVIg treatment to the initial response was significantly shorter in the rapid-response group (5 [3\u20136.25] days vs. 10.5[8.75\u201315] days in slow-response GBS, <jats:italic>p<\/jats:italic> &amp;lt; 0.001). Hughes score at 1 month was worse than the rapid responders (Fisher's exact test, <jats:italic>p<\/jats:italic> = 0.006). Survival analysis (Kaplan\u2013Meier) with respect to regaining the ability to walk independently (Hughes Functional Grading Scale of 2) within 1 month after onset was significantly different among the two groups (log-rank test for trend, <jats:italic>p<\/jats:italic> = 0.024). The abnormal levels of cerebral spinal fluid proteins and autonomic dysfunction were more frequent in the slow-response group than those in the rapid group (<jats:italic>p<\/jats:italic> &amp;lt; 0.05).<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> The rate of response to IVIg treatment was correlated with short-term outcomes in children with GBS and had predictive value for prognosis. The role of patient's initial responses to treatment could be significantly valuable in developing more effective and efficient treatment options.<\/jats:p>","DOI":"10.3389\/fneur.2021.746389","type":"journal-article","created":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T08:29:26Z","timestamp":1636100966000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Association Between the Rate of Treatment Response and Short-Term Outcomes in Childhood Guillain-Barr\u00e9 Syndrome"],"prefix":"10.3389","volume":"12","author":[{"given":"Mei","family":"Jin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Libo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weijin","family":"Geng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziwei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunzhen","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingru","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzhen","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,11,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/S0140-6736(21)00517-1","article-title":"Guillain-Barr\u00e9 syndrome","volume":"397","author":"Shahrizaila","year":"2021","journal-title":"Lancet."},{"key":"B2","doi-asserted-by":"publisher","first-page":"CD002063","DOI":"10.1002\/14651858.CD002063.pub6","article-title":"Intravenous immunoglobulin for Guillain-Barr\u00e9 Syndrome","volume":"19","author":"Hughes","year":"2014","journal-title":"Cochrane Database Syst Rev."},{"key":"B3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1055\/s-2007-981686","article-title":"Clinical presentation and course of childhood Guillain-Barr\u00e9 syndrome: a prospective multicentre study","volume":"38","author":"Korinthenberg","year":"2007","journal-title":"Neuropediatrics."},{"key":"B4","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1136\/jnnp-2011-301882","article-title":"Outcome and its predictors in Guillain-Barre syndrome","volume":"83","author":"Rajabally","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B5","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.vaccine.2010.06.003","article-title":"Guillain-Barr\u00e9 syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data","volume":"29","author":"Sejvar","year":"2011","journal-title":"Vaccine."},{"key":"B6","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/S0140-6736(78)92644-2","article-title":"Controlled trial prednisolone in acute polyneuropathy","volume":"2","author":"Hughes","year":"1978","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1016\/S0140-6736(05)67665-9","article-title":"Guillain-Barr\u00e9 syndrome","volume":"366","author":"Hughes","year":"2005","journal-title":"Lancet."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1212\/WNL.0b013e3182904fcc","article-title":"Mortality in Guillain-Barre syndrome","volume":"80","author":"van den Berg","year":"2013","journal-title":"Neurology."},{"key":"B9","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1212\/WNL.0b013e3182104407","article-title":"Early recognition of poor prognosis in Guillain-Barre' syndrome","volume":"76","author":"Walgaard","year":"2011","journal-title":"Neurology."},{"key":"B10","doi-asserted-by":"publisher","first-page":"781787","DOI":"10.1002\/ana.21976","article-title":"Prediction of respiratory insufficiency in Guillain-Barr\u00e9 syndrome","volume":"67","author":"Walgaard","year":"2010","journal-title":"Ann Neurol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/nrneurol.2014.121","article-title":"Guillain-Barr\u00e9 syndrome: pathogenesis, diagnosis, treatment and prognosis","volume":"10","author":"van den Berg","year":"2014","journal-title":"Nat Rev Neurol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3233\/JND-200581","article-title":"Cerebrospinal fluid protein level and mechanical ventilation in Guillain-Barr\u00e9 syndrome patients","volume":"8","author":"Davalosa","year":"2021","journal-title":"J. Neuromuscular Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.bbagen.2007.10.001","article-title":"Antibodies against gangliosides and ganglioside complexes in Guillain\u2013Barr\u00e9 syndrome: new aspects of research","volume":"1780","author":"Kusunoki","year":"2008","journal-title":"Biochim Biophys Acta."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1093\/brain\/awg207","article-title":"Distinct time pattern of complement activation and cytotoxic T cell response in Guillain-Barr\u00e9 syndrome","volume":"126","author":"Wanschitz","year":"2003","journal-title":"Brain."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e5976","DOI":"10.1212\/WNL.0000000000007719","article-title":"Current treatment practice of Guillain-Barr\u00e9 syndrome","volume":"93","author":"Verboon","year":"2019","journal-title":"Neurology."},{"key":"B16","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s10286-018-0542-y","article-title":"Autonomic involvement in Guillain-Barr\u00e9 syndrome: an update","volume":"29","author":"Zaeem","year":"2019","journal-title":"Clin Auton Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"58158","DOI":"10.1177\/0883073811420872","article-title":"Autonomic dysfunction in childhood Guillain-Barr\u00e9 syndrome","volume":"27","author":"DiMario","year":"2012","journal-title":"J Child Neurol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1542\/peds.2005-3032","article-title":"Pediatric autonomic disorders","volume":"118","author":"Axelrod","year":"2006","journal-title":"Pediatrics."},{"key":"B19","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/s41582-019-0250-9","article-title":"Diagnosis and management of Guillain-Barr\u00e9 syndrome in ten steps","volume":"15","author":"Leonhard","year":"2019","journal-title":"Nat Rev Neurol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1177\/0883073819900718","article-title":"Zipper method of Hacettepe: a promising method of immunomodulation","volume":"35","author":"Bayrakci","year":"2020","journal-title":"J Child Neurol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"399","DOI":"10.3389\/fneur.2018.00399","article-title":"Motor nerve conduction block predicting outcome of Guillain-Barre syndrome","volume":"9","author":"Niu","year":"2018","journal-title":"Front Neurol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1136\/jnnp-2014-309945","article-title":"The correlation between the change of distal motor latency of the median nerve and the abundant A-waves in Guillain-Barr\u00e9 syndrome","volume":"87","author":"Kadoya","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/j.clinph.2011.10.005","article-title":"A-waves in Guillain-Barr\u00e9 syndrome: correlation with electrophysiological subtypes and antiganglioside antibodies","volume":"123","author":"Kawakami","year":"2012","journal-title":"Clin Neurophysiol."}],"updated-by":[{"DOI":"10.3389\/fneur.2022.850357","type":"corrigendum","label":"Corrigendum","source":"publisher","updated":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T00:00:00Z","timestamp":1643328000000}}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.746389\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T15:22:48Z","timestamp":1643296968000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.746389\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,5]]},"references-count":23,"alternative-id":["10.3389\/fneur.2021.746389"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2021.746389","relation":{"corrigendum":[{"id-type":"doi","id":"10.3389\/fneur.2022.850357","asserted-by":"object"}]},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,5]]},"article-number":"746389"}}